Impact of mycophenolate mofetil intolerance on early results of kidney transplantation

Transplantation Proceedings

Volumn 37, Issue 8, 2005, Pages 3276-3279

  Kahu, J ^a,c   Kyllonen L ^b   Salmela, K ^b  

^a TARTU UNIVERSITY HOSPITAL   (Estonia)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c TARTU UNIVERSITY CLINICS   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

CONFERENCE PAPER; CORRELATION ANALYSIS; CYTOPENIA; DIARRHEA; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MEDICAL RECORD; PRIORITY JOURNAL; REDUCTION; THROMBOCYTOPENIA;

ADULT; ALANINE TRANSAMINASE; DRUG HYPERSENSITIVITY; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME;

EID: 27844475697     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.09.014     Document Type: Conference Paper

References (12)

1. EBPG Expert Group on Renal Transplantation European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.9.2. Haematological complications Nephrol Dial Transplant 17 suppl 4 2002 49
2. K.T. Salmela, L.E.J. Kyllönen Two decades of experience with cyclosporine in renal transplantation in Helsinki Transplant Proc 36 suppl 2 2004 S94
3. R.P. Pelletier, B. Akin, M.L. Henry The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation Clin Transplantation 17 2003 200
4. G.A. Knoll, I. MacDonald, A. Khan Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation J Am Soc Nephrol 14 2003 2381
5. European Mycophenolate Mofetil Cooperative Study Group Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection Lancet 345 1995 1321
6. J.P. Squifflet, L. Backman, K. Claesson Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients Transplantation 72 2001 63
7. B. Kaplan, H.U. Meier-Kriesche, G. Friedman The effect of renal insufficiency on mycophenolic acid protein binding J Clin Pharmacol 39 1999 715
8. M.D. Hale, A.J. Nicholls, R.E. Bullingham The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation Clin Pharmacol Ther 64 1998 672
9. D.R. Kuypers, K. Claes, P. Evenepoel Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration a prospective study in 100 de nove renal allograft recipients J Clin Pharmacol 43 2003 866
10. M. Mourad, J. Malaise Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil Clin Chem 47 2001 88
11. H.W. Sollinger U.S. Renal Transplant Mycophenolate Mofetil Study Group Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients Transplantation 60 1995 225
12. T. van Gelder, L.B. Hilbrands, Y. Vanrenterghem A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation Transplantation 68 1999 261